Alex McDonald: Much Needed Information on the Management of LVT
Alex McDonald, Clinical Pharmacy Specialist at Spartanburg Regional Healthcare System, reposted from RPTH Journal on LinkedIn:
”Much needed information on the management of LVT.
Stay tuned for more data regarding the use of the elevated intensity phase of apixaban (7 days) and rivaroxaban (21 day).
Prefer not to call it a loading dose since it is more for clot dynamics than for pharmacokinetics.”
Quoting RPTH Journal‘s post:
”Left ventricular thrombus (LVT) is a dangerous complication. Until now, we’ve had limited evidence on how DOACs compare with VKAs.
A new Mayo Clinic multi-site study of 182 patients sheds some light:
- DOACs and VKAs had similar rates of embolism and thrombus resolution.
- VKAs, however, carried more major bleeding.
- The first 8 weeks remain the highest-risk window for embolization — suggesting a loading dose of DOAC could be worth exploring.
Important data for anyone managing cardiomyopathy or LVT.”
Read the full article in RPTH.
Article: Comparison of direct oral anticoagulants and vitamin K antagonists in the treatment of left ventricular thrombi: a retrospective cohort study
Authors: Hossam Elbenawi, Kirsten Lipps, Samuel Heller Jr., David A. Liedl, Raymond C. Shields, Ana I. Casanegra, Stanislav Henkin, Thom W. Rooke, Paul W. Wennberg, Waldemar E. Wysokinski, Robert D. McBane, Damon E. Houghton
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 5, 2026, 19:00Kausik Ray: Comparing Lipid Management in France vs. Rest of Europe for High Cardiovascular Risk Patients
-
Apr 5, 2026, 18:22Omar Adwan: Systematic Approach to Blood Smear Examination
-
Apr 5, 2026, 18:05Heghine Khachatryan: Rethinking Hemostatic Targets in Pregnancy for von Willebrand Disease
-
Apr 5, 2026, 17:45Matthew Walls: Recognising CAD PRS as a New ‘Risk Enhancing Factor’ in the 2026 ACC/AHA Guidelines
-
Apr 5, 2026, 17:44Philip A. Chan: Occasional Heavy Drinking Leads to 3 Times Higher Liver Fibrosis Risk in MASLD
-
Apr 5, 2026, 17:42Josu de la Fuente: Real World Data Shows Significant Risk of Subsequent HCT in SCD and Thalassemia
-
Apr 5, 2026, 17:41Gevorg Yaghjyan: Attending an AI Conference on AI in Clinical Medicine, Research and Education
-
Apr 5, 2026, 17:41Ifeanyichukwu Ifechidere: The Mastermind of Clotting – A Thrombin Story
-
Apr 5, 2026, 17:38Thomas Ichim: Making iPSC Cells from Menstrual Blood Stem Cells